Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Renal Cell 23Glioblastoma 13Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Prostatic Neoplasms 9Neoplasms 9Breast Neoplasms 9Brain Neoplasms 9Neoplasm Metastasis 8Kidney Neoplasms 8Gliosarcoma 8Melanoma 7Sarcoma 6Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Oligodendroglioma 5Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Glioma 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Lymphoma, B-Cell, Marginal Zone 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Rhabdomyosarcoma 3Osteosarcoma 3

Interventions

Vincristine 3Topotecan 3Stem Cell Transplantation 3Radiation 3Platinum 3Melphalan 3Doxorubicin 3Cyclophosphamide 3Congresses as Topic 3Cisplatin 31,2-diaminocyclohexaneplatinum II citrate 3sargramostim 2dinutuximab 2Isotretinoin 2Etoposide 2Colony-Stimulating Factors 2Busulfan 2temsirolimus 1etoposide phosphate 1Thiotepa 1Temozolomide 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Peripheral Blood Stem Cell Transplantation 1Mesna 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ganglioneuroblastoma × temsirolimus × Clear all
NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡